Arbutus Reports First Quarter 2023 Financial Results and Corporate Update
May 04, 2023 07:30 ET
|
Arbutus Biopharma Corporation
Additional AB-729 off-treatment data highlighted in an oral presentation at the Global Hepatitis Summit 2023 Dosed first subject in Phase 1 clinical trial with oral RNA Destabilizer, AB-161 Filed...